- ￥190 - 390
- Solarbio
- 北京
- IS2630
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Sparfloxacin
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
110871-86-8
- 规格：
500mg/100mg
| 规格： | 500mg | 产品价格： | ￥390.0 |
|---|---|---|---|
| 规格： | 100mg | 产品价格： | ￥190.0 |
| 基本信息 | |
| CAS | No.110871-86-8 |
| 中文名称 | 司帕沙星 |
| 英文名称 | Sparfloxacin |
| 分子式 | C19H22F2N4O3 |
| 分子量 | 392.4 |
| 溶解性 | Soluble in DMSO(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00869619 |
| SMILES | C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F |
| InChIKey | DZZWHBIBMUVIIW-DTORHVGOSA-N |
| InChI | InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10，23H，3-6，22H2，1-2H3，(H，27，28)/t8-，9+ |
| PubChem CID | 60464 |
| 靶点 | Bacterial |
| 通路 | Anti-infection |
| 背景说明 | Sparfloxacin 是一种喹诺酮类抗生素，具有广谱的抗菌活性。 |
| 生物活性 | Sparfloxacin 是一种氟喹诺酮类抗生素，具有广泛而有效的抗菌活性。[1] |
| In Vitro | Sparfloxacin，Its MICs for 90% of the strains tested were 0.1 to 0.78 micrograms/ml against gram-positive organisms，such as members of the genera Staphylococcus，Streptococcus，and Enterococcus，and 0.0125 to 1.56 micrograms/ml against gram-negative organisms，such as members of the family Enterobacteriaceae and the genera Pseudomonas，Branhamella，Campylobacter，Haemophilus，and Neisseria. Its MICs were 0.025 to 0.78 micrograms/ml against glucose nonfermenters，such as members of the genera Xanthomonas，Acinetobacter，Alcaligenes，Moraxella，Flavobacterium，and Brucella; 0.2 to 0.78 micrograms/ml against anaerobes，such as Clostridium perfringens and Bacteroides fragilis; 0.0125 to 0.05 micrograms/ml against Legionella spp.; 0.0125 to 0.2 micrograms/ml against Mycoplasma spp.; 0.031 to 0.063 micrograms/ml against Chlamydia spp.; and 0.1 to 0.3 micrograms/ml against Mycobacterium spp. The potencies of sparfloxacinagainst gram-negative organisms were comparable to those of ciprofloxacin and higher than those of ofloxacin，enoxacin，and norfloxacin. The potencies of sparfloxacin against gram-positive organisms，glucose nonfermenters，anaerobes，Mycoplasma spp.，Chlamydia spp.，and Mycobacterium spp. were generally higher than those of the quinolones with which sparfloxacin was compared.[1]The targeting of gyrase by sparfloxacin in S. pneumoniae but of topoisomerase IV by ciprofloxacin.[2] |
| 细胞实验 | Sparfloxacin showed good oral efficacy against systemic infections with Staphylococcus aureus，Streptococcus pyogenes，Streptococcus pneumoniae，Escherichia coli，and Pseudomonas aeruginosa in mice. Its efficacy was better when a daily dose was given once than when it was given in two doses. Good efficacies of the orally administered drug were also observed in pulmonary，dermal，and urinary tract infection models in mice. The in vivo efficacies of Sparfloxacin were equal to or better than those of ciprofloxacin，ofloxacin，enoxacin，and norfloxacin.[1] |
| 数据来源文献 | [1]. Nakamura S，et al. In vitro and in vivo antibacterial activities of AT-4140，a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167-73. [2]. Pan XS，et al. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
)同时发生改变[7]。 肺炎链球菌是引起社区获得性肺炎的重要致病菌。目前，国内PRSP的发生率在4％左右，明显低于欧洲国家，在亚洲也属于中等水平，且MIC多小于1mg／L，因此，在社区获得性肺部感染病原菌中，PRSP尚不构成严重威胁，青霉素仍可作为首选治疗药物。但是耐药没有国界，中国日前PRSP发生率尚低．但决不意味着不要重视，而是应该进一步加强PRSP的耐药监测。对于PRSP感染临床治疗推荐使用头孢噻肟／头孢曲松、新喹诺酮类（如司帕沙星)。若属PRSP严重感染则需应用万古
技术资料暂无技术资料 索取技术资料
IS2630 司帕沙星 抗感染 索莱宝
￥190 - 390
